HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Chattem purchase

This article was originally published in The Rose Sheet

Executive Summary

Johnson & Johnson's anti-cavity mouthwash brand ACT will be acquired by Chattem under an agreement in which the firm will pay $410 mil. in cash for five J&J and Pfizer Consumer Healthcare brands, Chattem announces Oct. 6. The transaction is subject to review and approval by the Federal Trade Commission and certain closing conditions, including J&J's acquisition of the Pfizer Consumer Healthcare division, which is expected to close by the end of the year (1"The Rose Sheet" July 3, 2006, p. 7). ACT would represent Chattem's first mouthwash brand; the firm also plans to acquire OTC brands Unisom, Cortizone, Kaopectate and Balmex. "These brands are responsive to advertising and can be extended with new products, which plays perfectly into our proven track record of growing brands through innovation and advertising," Chattem says. The pending transaction will be accretive to Chattem's earnings per share in 2007 and provides "excellent long-term growth opportunities for both sales and earnings," firm says...

You may also be interested in...

Chattem Sales Up 51% Behind Ongoing Push From J&J Acquisitions

Brands Chattem acquired from Johnson & Johnson and continued growth of its own Gold Bond and Icy Hot drove a 51 percent increase in third-quarter revenues, the firm reported Sept. 27

Chattem completes acquisition

Chattem announces Jan. 2 it has closed its agreement to purchase, for $410 mil. in cash, the U.S. rights to five brands divested in connection with Johnson & Johnson's acquisition of Pfizer's Consumer Healthcare business, including anti-cavity mouthwash brand ACT (1"The Rose Sheet" Oct. 9, 2006, In Brief). "We are very excited to add these leading brands to the company's existing portfolio of quality products," Chattem CEO and Chairman Zan Guerry says. Chattem will replace Fidelity Bankshares in Standard & Poor's SmallCap 600 index after the close of trading Jan. 5...

Gold Bond, Selsun Line Extensions To Help Drive Chattem’s 2007 Sales

Chattem will rely on the launch of line extensions under core brands to drive revenue growth in 2007, the company announced during an Oct. 10 third quarter analyst call

Related Content




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts